Multiple Sclerosis Therapeutics Market Forecast till 2025

Multiple sclerosis (MS) is a disabling autoimmune disease affecting the brain and the spinal cord, eventually causing nerve deterioration or permanent damage. The types of MS include relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS). RPMS is the most common type characterized by defined attacks with increasing neurological symptoms, PPMS is the rare form characterized by gradual progression of disease, whereas SPMS is commonly identified in people living with relapsed-remitting MS. The most common symptoms of the disease include partial or complete vision loss, prolonged vision loss, lack of coordination and slurred speech. Click To Continue Reading on Multiple Sclerosis Therapeutics Market A combination of genetic and environmental factors is responsible for the occurrence of the condition. According to a study by International Progressive Alliance, 2013, MS is two to three times more common in women than in men, suggesting that hormones play a significant role in determining susceptibility to the disease. Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000 population. North America dominates the multiple sclerosis therapeutics market owing to the high prevalence of the condition and the rising economic burden of the disease leading to the adoption of novel therapeutics. According to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Higher therapy cost is restraining the growth of the multiple sclerosis therapeutics market. Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1310 Key Vendors: Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc. Article Tags: Multiple Sclerosis Therapeutics, Sclerosis Therapeutics Market, Multiple Sclerosis, Sclerosis Therapeutics, Therapeutics Market Source: Free Articles from ArticlesFactory.com

The male sexual problem can be effectively treated by the urologist

The male sexual problem doctor in Ghaziabad can treat your problem effectively as well as efficiently. Therefore, you should knock the door of the best urologist in Ghaziabad, who will look after your issue. Why sexual dysfunction in male occurs/ The issue such as male sexual dysfunction transpire in a condition when a man is not able to perform sexual activities with her partner or he is viable for fully engaged sexual intercourse. The cause for this dysfunctionality can be physical or sometime psychological. The male sexual problem such as may occur at anytime during the sexual cycle, such as excitement, plateau, orgasm and resolution. The sexual problems that is very common in men are erectile dysfunction, ejaculation disorders, inhibited sexual desire, low testosterone and peyronie disease. However, it is fortunate that you do not have to live with this forever. What are the causes of sexual dysfunction in male? As a matter of fact, the issue of male sexual dysfunction hardly emerges in the form of serious health issue. However, it makes them feel anxious, stressed, inadequate and depressed. So, it affects highly on emotional and psychological lever. It may also cause relationship problem. Some common causes of the sexual dysfunction in the male are listed below: Low testosterone level Excessive use of alcohol, drugs and regular smoking habit Consistent use of some medicine may also cause sexual dysfunction in men Blood vessel disorders such as hardening of the arteries and high blood pressure Stroke and nerve impairment due to diabetes or surgery. Kidney disease Liver disease Medical issue pertinent to neurological disorders such as multiple sclerosis and Parkinson's Worrying so much about sexual performance Past sexual trauma Stress pertinent to work Marital or relationship problems Feeling of guilty and depression Hormonal problems or hormonal imbalance, such as low testosterone Vascular disease Heart disease Treatment is available According to the best urologist in Noida, although male sexual dysfunction issue is very common problem affecting men of all ages, but, it is more found in increasing age. The treatment for these problems are quite available at urologist clinic. Treatment option for male sexual dysfunction: All the symptoms or underlying causes of the male sexual problem may vary from individual to individual. Thus, according to the male sexual problem doctor in Ghaziabad Feature Articles, the treatment is determined on the basis of patient feedback as well as medical findings. The treatment may include as such: Source: Free Articles from ArticlesFactory.com

Vascular Closure Device Market Forecast to 2025

Vascular closure devices (VCDs) are medical devices used to achieve vascular hemostasis after the puncture of femoral artery during diagnostic angiography procedures or interventional procedures. VCDs are developed as an alternative of mechanical compression. Although mechanical compression is effective method for treatment of hemostasis, it take a longer time period to effectively achieve hemostasis than vascular closure devices. VCDs has been available in the U.S. since 1995, when St. Jude Medical, Inc. received the approval for VasoSeal device. Since then, number of leading medical devices such as Abbott Laboratories, Medtronic Plc, and Terumo Corporation companies have entered in the market. Click To Continue Reading on Vascular Closure Device Market Vascular closure devices are medical devices used in sealing puncture of the femoral artery in patients who have undergone diagnostic angiography procedures or interventional procedures. Vascular closure devices are alternative to manual compression method, manually compression takes longer time, depending on the size of the plastic sheath placed in the artery. Vascular closure devices provide immediate sealing of the femoral artery access site, which is not the case with mechanical or manual compression. Increasing demand for diagnostic angiography procedures due to increasing prevalence of Coronary heart disease (CHD) is expected to increase demand for vascular closure device in near future. For instance according to the research published in Centers for Disease Control and Prevention (CDC) in 2017, Coronary heart disease (CHD) is one common type of heart disease, which causes about 370,000 deaths in U.S. annually. Furthermore the launch of innovative vascular closure devices in market is also expected create lucrative environment for market growth. For instance in 2014, AccessClosure Inc. launched Mynx Ace vascular closure device at annual scientific session of the American College of Cardiology in Washington, DC. Furthermore, in 2017, Vasorum Ltd. launched Celt ACD second generation vascular closure device in the U.S. market. Vascular closure device are primarily used for vascular hemostasis after puncture of the femoral artery during angiography. Angiography is an imaging technique used to visualize interior of blood vessels including artery. The technique has been increasingly used for finding out if the arteries are blocked, closed or narrowed. According to research published by World Health Organization (WHO) in 2017, about 17.7 million people died from cardiovascular diseases in 2015, which is about 31% of all global deaths. Among these death around 7.4 million death were due to coronary heart disease and 6.7 million were due to stroke. As the prevalence of the cardiovascular disease is increasing, the demand for angiography, a diagnosis technique, is expected to increase which in turn will lead to growth in global vascular closure devices market. This market has witnessed few recalls, which has proved to be major restraining factor for market growth. For instance, in 2017 Abbott Vascular recall 66 lots of the StarClose SE Vascular system due to difficulty in deploying the clip. Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1330 Key Vendors: Abbott Laboratories, Medtronic Plc., Transluminal Technologies LLC, Cardinal Health, Inc., Cardiva Medical, Inc., Terumo Corporation, Essential Medical, Inc., Vascular Closure Systems, Inc., Vivasure Medical Ltd., Vasorum Ltd. , and Morris Innovative Inc. Article Tags: Vascular Closure Device, Closure Device Market, Vascular Closure Devices, Diagnostic Angiography Procedures, Coronary Heart Disease, Vascular Closure, Closure Device, Device Market, Closure Devices, Medical Devices, Femoral Artery, Diagnostic Angiography, Angiography Procedures, Coronary Heart, Heart Disease Source: Free Articles from ArticlesFactory.com